Patents Represented by Attorney Elaine M. Ramesh
  • Patent number: 7208633
    Abstract: A production method of a compound represented by the formula wherein R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e and R2f are the same or different and each is a hydrogen atom and the like, and R3, R4, R5, R6, R7, R8, R9 and R10 are the same or different and each is a hydrogen atom and the like, or a salt thereof, which comprises reacting a compound represented by the formula wherein X is a leaving group and other symbols are as defined above, or a salt thereof, with a phosphine-borane complex represented by the formula wherein the symbols are as defined above, or a salt thereof, in a solvent in the presence of an amine and a nickel catalyst, is provided.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: April 24, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mitsutaka Goto, Mitsuhisa Yamano
  • Patent number: 7208495
    Abstract: A compound represented by the formula: (wherein, R1 and R2 are the same or different and each represents a hydrogen atom, hydrocarbon group or heterocyclic group, or R1 and R2 may form, together with the adjacent carbon atom, a 3–8 membered iso- or heterocyclic group, R3 represents a cyclic group, a hydroxy group, a mercapto group that may have oxo, or an amino group, R4 represents a hydrogen atom, a hydrocarbon group, a hydroxy group, a mercapto group which may have oxo, or an amino group, or R2 and R4 may link together to form a double bond, X represents a bond or a linear hydrocarbon group, W represents an oxygen atom or a sulfur atom, ring B represents a 5–8 membered nitrogen-containing heterocyclic group, ring C represents a benzene ring, and— represents a single bond or a double bond), or a salt or a prodrug thereof that has excellent neurodegenerative inhibitory activity and brain penetrability, and is useful as an agent for preventing/treating neurodegenerative diseases.
    Type: Grant
    Filed: July 4, 2002
    Date of Patent: April 24, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigenori Ohkawa, Masaomi Miyamoto, Masahiro Okura, Tetsuya Tsukamoto
  • Patent number: 7183276
    Abstract: The present invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group, A is an optionally substituted cyclic amino group or —NR2—W—D wherein R2 is a hydrogen atom or an alkyl group, W is a bond or a divalent acyclic hydrocarbon group, and D is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom, and Y is a bond or a divalent acyclic hydrocarbon group, or a salt thereof, which is useful for the prophylaxis or treatment of diabetic neuropathy and the like.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: February 27, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nozomu Sakai, Yu Momose, Katsuhito Murase, Masatoshi Hazama
  • Patent number: 7169799
    Abstract: The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole·n?H2O (wherein n? is about 0 to about 0.1) or a salt thereof, which characteristically includes crystallization from an organic solvent solution or suspension in which (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-benzimidazole·nH2O (wherein n is about 0.1 to about 1.0) or a salt thereof has been dissolved or suspended, and the like, and provides a convenient method for efficiently producing an optically active sulfoxide derivative having an extremely high enantiomer excess in high yield at an industrial large scale.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: January 30, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hideo Hashimoto, Hideaki Maruyama
  • Patent number: 7166762
    Abstract: A non-human mammal which is usefully and effectively applicable to the screening of a substance to be employed for preventing and treating heart failure. This animal is an animal model of heart failure prepared by starting both coronary stenosis and the stenosis of arteries other than the coronary artery and the abdominal artery of a non-human mammal within the same period of time.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: January 23, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuji Fujiwara, Shota Ikeda, Keiji Kusumoto
  • Patent number: 7160887
    Abstract: Compounds of a formula: wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; R1 represents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; R2 represents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents —CO—, —CON(Ra)—, COO—, N(Ra)CON(Rb)—, —N(Ra)COO—, —N(Ra)SO2—, N(Ra)—, —O—, —S—, —SO— or —SO2— (in which Ra and Rb each independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from; (i) a C1-6 alkyl group, (ii) a halogeno-C1-6 alkyl group, (iii) a phenyl group, (iv) a benzyl group, (v) an optionally-substituted amino group, (vi) an optionally
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: January 9, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoru Oi, Nobuhiro Suzuki, Kazuyoshi Aso, Yoshihiro Banno
  • Patent number: 7157584
    Abstract: The present invention relates to a compound represented by the formula (I) wherein R1 is a group represented by the formula wherein R2, R3, R4, R5, R6, R7 and R8 are each independently a hydrogen atom or a C1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: January 2, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takanobu Kuroita, Hiroki Sakamoto, Mami Ojima
  • Patent number: 7138249
    Abstract: The screening method for a compound or a salt thereof that alters the binding property between Neuromedin U or a salt thereof and TGR-1 or a salt thereof, characterized by using Neuromedin U, a derivative thereof or a salt thereof and TGR-1 or a salt thereof, can be useful for screening a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc. A TGR-1 antagonist can be useful as a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: November 21, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuji Hinuma, Yasushi Shintani, Masaki Hosoya, Ryo Fujii, Takeo Moriya, Hideki Matsui, Shoichi Okubo
  • Patent number: 7115750
    Abstract: A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R1 and R2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.
    Type: Grant
    Filed: September 19, 2000
    Date of Patent: October 3, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kaneyoshi Kato, Jun Terauchi, Masaaki Mori, Nobuhiro Suzuki, Yukio Shimomura, Shiro Takekawa, Yuji Ishihara
  • Patent number: 7109200
    Abstract: Novel carbamate derivatives which are useful as drugs because of inhibiting activated blood coagulation factor X and thus exerting an anticoagulant effect. Compounds represented by the formula: wherein R1 represents a group represented by the formula: (wherein Y1 represents CH?CH, etc.), which may be substituted, etc.; the ring A represents an oxo-substituted nitrogen-containing heterocyclic ring which may be further substituted; R2 represents a hydrogen atom, optionally substituted C1-4 alkyl, etc.; R3 represents optionally substituted C1-4 alkyl, etc.; and Z represents an optionally substituted nitrogen containing heterocyclic group, etc., or salts thereof.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: September 19, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Fumio Itoh, Hiroshi Banno, Masaki Kawamura, Shuji Kitamura
  • Patent number: 7105572
    Abstract: An emulsion composition containing a compound represented by the formula: wherein R, R0, Ar and n are as defined in the specification or a salt thereof or a prodrug thereof, wherein the composition is adjusted to have a pH of not more than about 6, shows improved stability of the compound, a salt thereof or a prodrug thereof, and realizes expression of superior efficacy.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: September 12, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Jun Sato
  • Patent number: 7091247
    Abstract: A novel biphenyl compound having GPR 14 antagonistic activity. It is a compound represented by the formula (I): wherein R1 represents hydrogen, etc.; X represents 1 to 12 spacers; A represents amino, etc., R2 and R3 each represents a hydrocarbon group, etc.; and rings B and C each represents an optionally further substituted benzene ring, or a salt thereof.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: August 15, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Tarui, Takashi Santo, Hiroyuki Watanabe, Kazuyoshi Aso, Tetsuo Miwa, Shiro Takekawa
  • Patent number: 7087597
    Abstract: Compounds of the formula wherein R1, R2, R3, R4, X and Y are as defined, which have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis, and the like; allergic diseases such as asthma, or disorders of male or female genital function and the like.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: August 8, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuo Miwa, Mitsuo Yamamoto, Takayuki Doi, Naoki Tarui
  • Patent number: 7084278
    Abstract: The present invention provides a method for producing an optically active ?-hydroxy ester compound represented by the general formula: wherein R1 represents an optionally substituted hydrocarbon group and the like, R2 represents a nitrogen-containing heterocyclic group different from R1, which is represented by the general formula: wherein the ring may be substituted and the like, R3 represents an optionally substituted hydrocarbon group and the like, R4 and R5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R1 and R2 are as defined above with a compound represented by the general formula: wherein R3, R4 and R5 are as defined above, and X is a halogen atom.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: August 1, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toru Yamano, Naohiro Taya, Akio Ojida
  • Patent number: 7084149
    Abstract: A composition containing a compound of the formula: wherein A is a nitrogen-containing heterocyclic group which may be substituted, R1 is a hydrogen atom, hydrocarbon group which may be substituted, or monocyclic aromatic heterocyclic group which may be substituted, R2 is a hydrogen atom or a lower alkyl group which may be substituted, R3, R4, R5, R6, R7, R8 and R9 are independently a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxy group which may be substituted, a thiol group which may be substituted, an amino group which may be substituted, an acyl group or a halogen atom, a salt thereof or a prodrug thereof has steroid C17,20-lyase inhibitory activity, and are useful for preventing and treating a mammal suffering from, for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: August 1, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
  • Patent number: 7070805
    Abstract: A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: July 4, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshihiro Shimizu, Masae Sugaya, Yoshinori Nakano
  • Patent number: 7067527
    Abstract: The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I): wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, —(CH2)q—, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of (wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: June 27, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Atsuo Baba, Haruhiko Makino, Isao Aoki, Toshiaki Nagata
  • Patent number: 7067537
    Abstract: The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: June 27, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Noritaka Kuroda, Yoshi Nara, Shohei Hashiguchi, Akihiro Tasaka, Masami Kusaka, Masuo Yamaoka, Tomohiro Kaku
  • Patent number: 7049403
    Abstract: The present invention relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt, (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: May 23, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasuaki Itoh, Nobuhiro Suzuki, Kazunori Nishi, Hideki Kizawa, Masataka Harada, Kazuhiro Ogi
  • Patent number: 7049441
    Abstract: According to the process as shown in the following scheme having a step for reacting Compound (I) with Compound (II) to produce Compound (III), benzylpiperidine compounds useful as synthesis starting materials of pharmaceutical agents, agricultural chemicals and the like can be produced conveniently by a short step: wherein R1 is a hydrogen atom or an amino-protecting group, R2 is a hydrogen atom, a hydrocarbon group optionally having substituents, an alkoxy group optionally having substituents or a heterocyclic group optionally having substituents, and R3 is a lower alkyl group.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: May 23, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shokyo Miki, Mitsuhiro Takeda, Koji Nakamoto